Intellistem Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

  • Investors
  • 4

Intellistem General Information

Description

Operator of a biotechnology platform designed to develop cell-based therapeutics for cancer treatment. The company offers non-engineered, off-the-shelf SSC Gamma Delta Cells that work synergistically with standard antibody therapies, enabling cancer treatment providers to improve therapeutic efficacy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 440 Davis Court
  • Suite 901
  • San Francisco, CA 94111
  • United States
+1 (415)
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • 440 Davis Court
  • Suite 901
  • San Francisco, CA 94111
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intellistem Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 12-Jul-2024 Cancelled Generating Revenue
4. Seed Round 16-Apr-2024 Completed Generating Revenue
3. Accelerator/Incubator 26-Apr-2021 Completed Startup
2. Accelerator/Incubator 28-Oct-2019 $175K $175K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Intellistem’s complete valuation and funding history, request access »

Intellistem Patents

Intellistem Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240344026-A1 Methods to activate gamma delta t cells for antibody dependent cellular cytotoxicity Pending 17-Apr-2023
WO-2024020700-A1 Combination therapy with potentiated antigen presenting cells Inactive 29-Jul-2022
WO-2024020699-A1 Potentiated antigen presenting cells Inactive 29-Jul-2022
US-20220193211-A1 Overexpression of immunoproteasome in host cells for generating antigen-presenting cells Inactive 18-Apr-2019
WO-2020210915-A1 Overexpression of immunoproteasome in host cells for generating antigen-presenting cells Inactive 18-Apr-2019 A61K39/3955
To view Intellistem’s complete patent history, request access »

Intellistem Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intellistem Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
REGEN Capital Venture Capital Minority
MIT Solve Accelerator/Incubator
Octane (California) Accelerator/Incubator
District 3 Innovation Center Accelerator/Incubator
To view Intellistem’s complete investors history, request access »

Intellistem FAQs

  • When was Intellistem founded?

    Intellistem was founded in 2019.

  • Where is Intellistem headquartered?

    Intellistem is headquartered in San Francisco, CA.

  • What is the size of Intellistem?

    Intellistem has 4 total employees.

  • What industry is Intellistem in?

    Intellistem’s primary industry is Biotechnology.

  • Is Intellistem a private or public company?

    Intellistem is a Private company.

  • What is Intellistem’s current revenue?

    The current revenue for Intellistem is .

  • How much funding has Intellistem raised over time?

    Intellistem has raised $1.38M.

  • Who are Intellistem’s investors?

    REGEN Capital, MIT Solve, Octane (California), and District 3 Innovation Center have invested in Intellistem.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process